Sanctuary Advisors LLC acquired a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 13,455 shares of the exchange traded fund’s stock, valued at approximately $1,247,000.
A number of other institutional investors have also recently bought and sold shares of the business. HBK Sorce Advisory LLC raised its position in shares of SPDR S&P Biotech ETF by 2.6% in the first quarter. HBK Sorce Advisory LLC now owns 4,538 shares of the exchange traded fund’s stock valued at $431,000 after buying an additional 113 shares in the last quarter. Intellectus Partners LLC increased its stake in SPDR S&P Biotech ETF by 1.0% during the 2nd quarter. Intellectus Partners LLC now owns 11,334 shares of the exchange traded fund’s stock worth $1,051,000 after acquiring an additional 113 shares during the period. Pacific Center for Financial Services raised its holdings in SPDR S&P Biotech ETF by 2.8% in the 1st quarter. Pacific Center for Financial Services now owns 4,359 shares of the exchange traded fund’s stock valued at $414,000 after acquiring an additional 118 shares in the last quarter. Kingsview Wealth Management LLC raised its holdings in SPDR S&P Biotech ETF by 3.8% in the 1st quarter. Kingsview Wealth Management LLC now owns 3,495 shares of the exchange traded fund’s stock valued at $332,000 after acquiring an additional 127 shares in the last quarter. Finally, Bourgeon Capital Management LLC lifted its position in shares of SPDR S&P Biotech ETF by 5.9% during the 2nd quarter. Bourgeon Capital Management LLC now owns 2,427 shares of the exchange traded fund’s stock valued at $225,000 after acquiring an additional 135 shares during the period.
SPDR S&P Biotech ETF Stock Performance
Shares of NYSEARCA XBI opened at $96.22 on Friday. The stock has a market capitalization of $7.33 billion, a P/E ratio of 11.47 and a beta of 1.11. The stock’s fifty day moving average is $98.50 and its 200 day moving average is $94.12. SPDR S&P Biotech ETF has a 52 week low of $63.80 and a 52 week high of $103.52.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.